Vol. 21/No. 14

Judging from the drug pipeline, the future of oncology is oral chemotherapy.

Efforts are underway to expedite the identification of therapies that offer promise for patients with glioblastoma

A panel of hematology-oncology experts discuss the emergence of biosimilar use in oncology.

A novel compound that uses abundant lipids in cancer cell membranes to deliver a radioisotope to the tumor environment shows early signs of efficacy in a range of B-cell malignancies.

Primary chemoablation with UGN-102 elicited encouraging responses in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer and may consequently be an appropriate nonsurgical treatment intervention for patients.

Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.

Edgardo Santos, MD, discusses the FDA approval of ramucirumab plus erlotinib for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

Thomas E. Stinchcombe, MD, discusses brigatinib’s mechanism as well as the next steps to advance the treatment paradigm for patients with ALK-positive NSCLC.

Findings from a preplanned analysis of the phase 4 CARD study demonstrated superior patient-reported outcomes with cabazitaxel in men with castration-resistant prostate cancer who received prior docetaxel and androgen receptor targeted therapy versus alternative AR-targeted treatment options.

These are disquieting times for clear and decisive messaging regarding vaccines.